MEI Pharma Statistics
Total Valuation
MEI Pharma has a market cap or net worth of $19.06 million. The enterprise value is -$25.83 million.
| Market Cap | 19.06M |
| Enterprise Value | -25.83M |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MEI Pharma has 6.66 million shares outstanding.
| Shares Outstanding | 6.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.39% |
| Owned by Institutions (%) | 43.32% |
| Float | 4.93M |
Valuation Ratios
The trailing PE ratio is 0.73.
| PE Ratio | 0.73 |
| Forward PE | n/a |
| PS Ratio | 0.29 |
| Forward PS | n/a |
| PB Ratio | 0.37 |
| P/FCF Ratio | n/a |
| PEG Ratio | 20.60 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.17, with a Debt / Equity ratio of 0.23.
| Current Ratio | 6.17 |
| Quick Ratio | n/a |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 0.42 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 48.30% and return on invested capital (ROIC) is 35.79%.
| Return on Equity (ROE) | 48.30% |
| Return on Assets (ROA) | 28.10% |
| Return on Capital (ROIC) | 35.79% |
| Revenue Per Employee | $1.45M |
| Profits Per Employee | $568,587 |
| Employee Count | 46 |
| Asset Turnover | 0.72 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.30% in the last 52 weeks. The beta is 0.73, so MEI Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -61.30% |
| 50-Day Moving Average | 2.92 |
| 200-Day Moving Average | 4.63 |
| Relative Strength Index (RSI) | 48.92 |
| Average Volume (20 Days) | 12,585 |
Short Selling Information
The latest short interest is 17,649, so 0.26% of the outstanding shares have been sold short.
| Short Interest | 17,649 |
| Short Previous Month | 14,500 |
| Short % of Shares Out | 0.26% |
| Short % of Float | 0.36% |
| Short Ratio (days to cover) | 0.84 |
Income Statement
In the last 12 months, MEI Pharma had revenue of $66.75 million and earned $26.16 million in profits. Earnings per share was $3.92.
| Revenue | 66.75M |
| Gross Profit | 66.75M |
| Operating Income | 22.44M |
| Pretax Income | 26.16M |
| Net Income | 26.16M |
| EBITDA | 28.01M |
| EBIT | 26.16M |
| Earnings Per Share (EPS) | $3.92 |
Balance Sheet
The company has $56.55 million in cash and $11.67 million in debt, giving a net cash position of $44.89 million or $6.74 per share.
| Cash & Cash Equivalents | 56.55M |
| Total Debt | 11.67M |
| Net Cash | 44.89M |
| Net Cash Per Share | $6.74 |
| Equity (Book Value) | 51.03M |
| Book Value Per Share | 7.66 |
| Working Capital | 49.75M |
Cash Flow
In the last 12 months, operating cash flow was -$43.78 million and capital expenditures -$48,000, giving a free cash flow of -$43.82 million.
| Operating Cash Flow | -43.78M |
| Capital Expenditures | -48,000 |
| Free Cash Flow | -43.82M |
| FCF Per Share | -$6.58 |
Margins
Gross margin is 100.00%, with operating and profit margins of 33.62% and 39.18%.
| Gross Margin | 100.00% |
| Operating Margin | 33.62% |
| Pretax Margin | 39.18% |
| Profit Margin | 39.18% |
| EBITDA Margin | 41.96% |
| EBIT Margin | 39.18% |
| FCF Margin | -65.65% |
Dividends & Yields
MEI Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 137.25% |
| FCF Yield | -229.98% |
Analyst Forecast
The average price target for MEI Pharma is $7.00, which is 144.76% higher than the current price. The consensus rating is "Hold".
| Price Target | $7.00 |
| Price Target Difference | 144.76% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | -12.18% |
| EPS Growth Forecast (5Y) | -24.89% |
Stock Splits
The last stock split was on April 17, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Apr 17, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
MEI Pharma has an Altman Z-Score of -3.71 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.71 |
| Piotroski F-Score | 5 |